A5028218082- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Genetic Neurodegenerative Diseases
- Immunotherapy and Immune Responses
- Mitochondrial Function and Pathology
- DNA Repair Mechanisms
- Renal and related cancers
- Neurological disorders and treatments
- Hematopoietic Stem Cell Transplantation
- Energy and Environment Impacts
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
German Center for Neurodegenerative Diseases
2023-2025
University of Bonn
2020
Medizinische Hochschule Hannover
2016-2017
Seed amplification assays (SAA) detect alpha-synuclein (aSYN) pathology in patient biomatrices such as cerebrospinal fluid (CSF)-potentially even before clinical manifestations. As CSF-based SAA are approaching broader use trials and research, ensuring that different laboratories obtain the same results becomes increasingly important. In this cross-laboratory, cross-aSYN-recombinant substrate cross-protocol round-robin test, we compared from a common set of 38 CSF samples measured...
Abstract In view of upcoming clinical trials, quantitative molecular markers accessible in peripheral blood are critical importance as prognostic or pharmacodynamic genetic neurodegenerative diseases such Spinocerebellar Ataxia Type 3 (SCA3), particular for signaling target engagement. this pilot study, we focused on the quantification ataxin-3, protein altered SCA3, human mononuclear cells (PBMCs) acquired from preataxic and ataxic SCA3 mutation carriers well healthy controls, a marker...
The European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative (ESMI) is a consortium established with the ambition to set up largest longitudinal trial-ready cohort of (SCA3/MJD), most common autosomal dominantly inherited ataxia worldwide. A major focus ESMI has been identification SCA3/MJD biomarkers enable future interventional studies. As biosample collection and processing variables significantly impact outcomes studies, biosampling procedures standardisation was done...